Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation

被引:199
作者
Cantu-Medellin, Nadiezhda [1 ,2 ]
Kelley, Eric E. [1 ,2 ]
机构
[1] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA 15213 USA
关键词
Free radicals; Hypoxia; Inflammation; Nitric oxide; Nitrite; Oxygen tension; Xanthine oxidoreductase; NITRIC-OXIDE; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; LUNG INJURY; REACTION-KINETICS; REDUCTION; DEHYDROGENASE; INHIBITION; BINDING; PLASMA;
D O I
10.1016/j.redox.2013.05.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Nearly 30 years have passed since the discovery of xanthine oxidoreductase (XOR) as a critical source of reactive species in ischemia/reperfusion injury. Since then, numerous inflammatory disease processes have been associated with elevated XOR activity and allied reactive species formation solidifying the ideology that enhancement of XOR activity equates to negative clinical outcomes. However, recent evidence may shatter this paradigm by describing a nitrate/nitrite reductase capacity for XOR whereby XOR may be considered a crucial source of beneficial (NO)-N-center dot under ischemic/hypoxic/acidic conditions; settings similar to those that limit the functional capacity of nitric oxide synthase. Herein, we review XOR-catalyzed reactive species generation and identify key microenvironmental factors whose interplay impacts the identity of the reactive species (oxidants vs. (NO)-N-center dot) produced. In doing so, we redefine existing dogma and shed new light on an enzyme that has weathered the evolutionary process not as gadfly but a crucial component in the maintenance of homeostasis. (C) 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license
引用
收藏
页码:353 / 358
页数:6
相关论文
共 52 条
[1]
BINDING OF HUMAN XANTHINE-OXIDASE TO SULFATED GLYCOSAMINOGLYCANS ON THE ENDOTHELIAL-CELL SURFACE [J].
ADACHI, T ;
FUKUSHIMA, T ;
USAMI, Y ;
HIRANO, K .
BIOCHEMICAL JOURNAL, 1993, 289 :523-527
[2]
Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats [J].
Alef, Matthew J. ;
Vallabhaneni, Raghuveer ;
Carchman, Evie ;
Morris, Sidney M., Jr. ;
Shiva, Sruti ;
Wang, Yinna ;
Kelley, Eric E. ;
Tarpey, Margaret M. ;
Gladwin, Mark T. ;
Tzeng, Edith ;
Zuckerbraun, Brian S. .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (04) :1646-1656
[3]
Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease [J].
Aslan, M ;
Ryan, TM ;
Adler, B ;
Townes, TM ;
Parks, DA ;
Thompson, JA ;
Tousson, A ;
Gladwin, MT ;
Patel, RP ;
Tarpey, MM ;
Batinic-Haberle, I ;
White, CR ;
Freeman, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) :15215-15220
[4]
Aslan M, 2004, CELL MOL BIOL, V50, P95
[5]
Nitrite confers protection against myocardial infarction:: Role of xanthine oxidoreductase, NADPH oxidase and KATP channels channels [J].
Baker, John E. ;
Su, Jidong ;
Fu, Xiangping ;
Hsu, Anna ;
Gross, Garrett J. ;
Tweddell, James S. ;
Hogg, Neil .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2007, 43 (04) :437-444
[6]
Ball EG, 1939, J BIOL CHEM, V128, P51
[7]
Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension [J].
Butler, R ;
Morris, AD ;
Belch, JJF ;
Hill, A ;
Struthers, AD .
HYPERTENSION, 2000, 35 (03) :746-751
[8]
Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: Insights regarding where, when and how [J].
Cantu-Medellin, Nadiezhda ;
Kelley, Eric E. .
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2013, 34 :19-26
[9]
Xanthine oxidoreductase is a regulator of adipogenesis and PPARγ activity [J].
Cheung, Kevin J. ;
Tzameli, Iphigenia ;
Pissios, Pavlos ;
Rovira, Ilsa ;
Gavrilova, Oksana ;
Ohtsubo, Toshio ;
Chen, Zhu ;
Finkel, Toren ;
Flier, Jeffrey S. ;
Friedman, Jeffrey M. .
CELL METABOLISM, 2007, 5 (02) :115-128
[10]
Xanthine oxidase is involved in free radical production in type 1 diabetes -: Protection by allopurinol [J].
Desco, MC ;
Asensi, A ;
Márquez, R ;
Martínez-Valls, J ;
Vento, M ;
Pallardó, FV ;
Sastre, J ;
Viña, J .
DIABETES, 2002, 51 (04) :1118-1124